Date and time

Event date: Wednesday, 20 Mar 2024
Time: 1pm-2pm
Location: Zoom

We are pleased to welcome Dr Silvia Gregori to deliver the next talk in our NHIP Advanced Therapies Satellite seminar series, on the topic of IL-10-modulated Dendritic cells: Present and Future.

 

In this session she will give an overview of the preclinical studies focused on the development and characterization of IL-10-modulated DC and on the future clinical development of these cells.

 

Silvia Gregori, PhD, is a Group Leader at the San Raffaele Telethon Institute for Gene Therapy (SR-TIGET), IRCCS Ospedale San Raffaele, Milan. Silvia Gregori was originally trained in cell and molecular biology and received her PhD from the University of Milan.

After a short period in the UK working on type 1 diabetes, she took a position at Roche Milano Ricerche with Prof. L. Adorini. During this period, she made important contributions unraveling networks of immunological tolerance, first by dissecting the role of Vitamin D3 and its analogues in modulating T cell responses in diabetes and in islet transplantation.

In 2001, she took a postdoctoral position in the group led by Prof. MG. Roncarolo at SR-Tiget, where she elucidated new mechanisms of suppression mediated by T regulatory type 1 (Tr1) cells and identified DC-10 as major subset of dendritic cells involved in Tr1 cell differentiation.

Currently she leads a research team focusing on the development of efficient therapeutic approaches to (re)-establish antigen-specific tolerance based on the use of in vitro generated tolerogenic DC as medicinal product. Beside this main project, she is also supervising several projects aim at better understanding and modulating immune responses and tolerance to specific antigens/transgenes in pre-clinical and clinical settings.

 

Silvia is the coordinator of the European Horizon project “IMMUTOL – Advanced Antigen-Specific Dendritic Cell-Based Therapy to Re-establish Tolerance in Immune-Mediated Diseases”. She is also coordinating national projects two AIRC (IG 2016 – N.18540; 2013 – N.14105) focused on the development of Treg-based therapy to prevent graft-versus host disease after BM transplantation and two Ricerca Finalizzata (RF-2016-02361372; RF-2019-12368847), and a PNRR-MAD-2022-12375994 projects focused on studying tolerogenic DC involvement in autoimmune diseases and in male infertility.

 

Register for this seminar here.

Date and time

Event date: Wednesday, 20 Mar 2024
Time: 1pm-2pm
Location: Zoom
Skip to content